The Role of Adjuvant Radiation Therapy for Stage i Endometrial Cancer: Does Meta-Analysis Reveal the Answer?

Journal of the National Cancer Institute

Volumn 104, Issue 21, 2012, Pages 1615-1616

  Eifel, Patricia J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; DEMOGRAPHY; EDITORIAL; ENDOMETRIUM CANCER; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; LYMPH NODE DISSECTION; MORBIDITY; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; UTERINE CERVIX CANCER; UTERUS CANCER;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 84869068045     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs434     Document Type: Editorial

References (10)

1. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and metaanalysis. J Natl Cancer Inst. 2012;104(21).
2. Kong A, Simera I, Collingwood M, et al. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol. 2007;18(10):1595-1604.
3. Spilker B. Meta-analysis. In: Spilker B, ed. Guide to Clinical Trials. New York: Raven Press;1991: 793-799.
4. USCSWG. United States Cancer Statistics: 1999-2008 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2012.
5. Kellert IM, Botterweck AA, Huveneers JA, et al. Trends in incidence of and mortality from uterine and ovarian cancer in Mid and South Limburg, The Netherlands, 1986-2003. Eur J Cancer Prev. 2009;18(1):85-89.
6. Kent DM, Hayward RA. Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification. JAMA. 2007;298(10):1209-1212.
7. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744-751.
8. Lindemann K, Onsrud M, Kristensen G, et al. Survival after radiation therapy for early-stage endometrial carcinoma: the Oslo study revisited after up to 43 years of follow-up. J Clin Oncol. 2012;30(suppl): abstr 5008.
9. Creutzberg CL, van Putten WL, Koper PC, et al.; PORTEC Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000; 355(9213):1404-1411.
10. Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: results of the randomized PORTEC-2 trial. Proc 44th Annu Meeting Am Soc Clin Oncol. 2008:181.